Clinical and economic factors important to anaesthetic choice for day-case surgery.

Abstract:

:Clinical and economic factors that are important to consider when selecting anaesthesia for day-case surgery can differ from those for inpatient anaesthesia. Patients undergoing day-case surgery tend to be healthier and have shorter durations of surgery. They expect less anxiety before surgery, amnesia for the surgical experience, a rapid return to normal (normal mentation with minimal pain and nausea) after surgery, and lower expenses. However, the latter 2 expectations can conflict; older generic drugs have lower acquisition costs but often impose longer recovery times. Longer recovery periods can increase costs by prolonging the time to discharge from labour-intensive areas such as the operating suite or the post-anaesthesia recovery unit. The challenge for today's anaesthetist is to use newer drugs judiciously to minimise their expense without compromising the rate or quality of recovery. Several approaches can secure these aims. Most apply the least anaesthetic needed. 'Least anaesthetic' may mean the particular form of anaesthetic (e.g. local infiltration with monitored anaesthesia care versus a general anaesthetic), or may mean the delivery of the smallest effective dose, perhaps guided by anaesthetic monitors such as end-tidal analysers or the bispectral index. For patients requiring general anaesthesia, a combination of several drugs usually secures the closest approach to the ideal. Drug combinations used usually include a short-acting properative anxiolytic (e.g. midazolam), intravenous propofol (a short-acting potent anxiolytic and amnestic agent) for induction of anaesthesia (and sometimes for maintenance) and primary maintenance of anaesthesia with inhaled nitrous oxide combined with a poorly soluble (low solubility produces rapid recovery; the least soluble is desflurane) potent inhaled anaesthetic delivered at a low inflow rate (to minimise cost). Although old, nitrous oxide is inexpensive and has favourable pharmacokinetic and cardiovascular advantages; however, it is limited in its anaesthetic/amnestic potency, and has the capacity to increase nausea. In children, induction of anaesthesia is often accomplished with sevoflurane rather than desflurane; although sevoflurane is modestly more soluble than desflurane, it is non-pungent whereas desflurane is pungent. Moderate- or short-acting opioids (fentanyl is popular) or nonsteroidal anti-inflammatory agents (especially ketorolac), or local anaesthetics are added to secure analgesia during and after surgery. Similarly, when needed, moderate- or short-acting muscle relaxants are selected. Before the end of anaesthesia, an intravenous antiemetic may be given. With this drug combination, patients usually awaken within minutes after anaesthesia and can often move themselves to the vehicle for transport to the recovery unit. These combinations of anaesthetics and techniques minimise use of expensive drugs while expediting recovery (again minimising cost) with minimal or no compromise in the quality of recovery.

journal_name

Pharmacoeconomics

journal_title

PharmacoEconomics

authors

Eger EI,White PF,Bogetz MS

doi

10.2165/00019053-200017030-00003

subject

Has Abstract

pub_date

2000-03-01 00:00:00

pages

245-62

issue

3

eissn

1170-7690

issn

1179-2027

journal_volume

17

pub_type

杂志文章,评审
  • Interferon-beta in multiple sclerosis. Can we control its costs?

    abstract::The recent licensing of interferon-beta for use in patients with multiple sclerosis has caused concern, in view of the equivocal evidence of efficacy, pressure of public expectation towards its use and the high expected cost if widespread use were to be sanctioned. Whether such alarm is justified remains a moot point....

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199711030-00002

    authors: Tolley KH,Whynes DK

    更新日期:1997-03-01 00:00:00

  • Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.

    abstract:OBJECTIVE:To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard diabetes therapy and weight ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200321070-00005

    authors: Maetzel A,Ruof J,Covington M,Wolf A

    更新日期:2003-01-01 00:00:00

  • A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.

    abstract:BACKGROUND:Carcinoid syndrome, a rare condition in patients with neuroendocrine tumours, characterised by flushing and diarrhoea, severely affects patients' quality of life. The current carcinoid syndrome standard of care includes somatostatin analogues, but some patients experience uncontrolled symptoms despite somato...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00896-5

    authors: Fust K,Maschio M,Kohli M,Singh S,Pritchard DM,Marteau F,Myrenfors P,Feuilly M

    更新日期:2020-06-01 00:00:00

  • Assessing the economic value of a new antidepressant. A willingness-to-pay approach.

    abstract::Using the method of willingness to pay (WTP), this study assesses the value of a new antidepressant, moclobemide, relative to that of tricyclic antidepressants (TCAs), which have equivalent efficacy but less favourable adverse effect profiles. From a published meta-analysis of controlled clinical trials, we identified...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章

    doi:10.2165/00019053-199508010-00006

    authors: O'Brien BJ,Novosel S,Torrance G,Streiner D

    更新日期:1995-07-01 00:00:00

  • Recent developments in decision-analytic modelling for economic evaluation.

    abstract::The past few years have seen rapid changes in the methods of decision-analytic modelling of healthcare programmes for the purposes of economic evaluation. This paper focuses on four developments in modelling that have emerged over the past few years or have become more widely used. First, no one optimal method for ext...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200624110-00002

    authors: Weinstein MC

    更新日期:2006-01-01 00:00:00

  • Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

    abstract:BACKGROUND:The ARTEMIS trial compared first-line antiretroviral therapy (ART) with lopinavir/ritonavir (LPV/r) to darunavir plus ritonavir (DRV + RTV) for HIV-1-infected subjects. In order to fully assess the implications of this study, economic modelling extrapolating over a longer term is required. OBJECTIVE:The aim...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-013-0048-3

    authors: Simpson KN,Pei PP,Möller J,Baran RW,Dietz B,Woodward W,Migliaccio-Walle K,Caro JJ

    更新日期:2013-05-01 00:00:00

  • Costs and effects associated with a community pharmacy-based smoking-cessation programme.

    abstract:OBJECTIVE:The aim of the study was to determine the costs and effects associated with a community pharmacy-based smoking-cessation programme in Northern Ireland, using the perspective of the payer in the main analysis. DESIGN AND SETTING:Data from a pilot study conducted in 2 community pharmacies in Northern Ireland w...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199814030-00008

    authors: Crealey GE,McElnay JC,Maguire TA,O'Neill C

    更新日期:1998-09-01 00:00:00

  • Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

    abstract::As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of vedolizumab (Takeda UK) to submit evidence of the clinical effectiveness and cost effectiveness of vedolizumab for the treatment of patients with moderate-to-severe active ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-015-0334-3

    authors: Essat M,Tappenden P,Ren S,Bessey A,Archer R,Wong R,Lobo A,Hoque S

    更新日期:2016-03-01 00:00:00

  • Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

    abstract:INTRODUCTION:Recent clinical trial results have demonstrated that, in patients with type 2 diabetes, second-line treatment of rosiglitazone in combination with metformin can lead to significant improvements in the control of fasting plasma glucose/ glycosylated haemoglobin A1c (HbA1c) after the failure of metformin mon...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-200624001-00003

    authors: Beale S,Bagust A,Shearer AT,Martin A,Hulme L

    更新日期:2006-01-01 00:00:00

  • Alcoholism. The cost of illness in the Federal Republic of Germany.

    abstract::The purpose of this study was to estimate the direct and indirect costs of alcoholism in the Federal Republic of Germany. Direct costs comprised treatment costs, while indirect costs consisted mainly of costs incurred as a result of work time lost, as well as costs related to premature retirement and premature mortali...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199610050-00006

    authors: Brecht JG,Poldrugo F,Schädlich PK

    更新日期:1996-11-01 00:00:00

  • Future drug prices and cost-effectiveness analyses.

    abstract:BACKGROUND:Cost-effectiveness analyses worldwide assume that the price of any single drug increases with inflation. New guidance from the Pharmaceutical Management Agency in New Zealand suggests that, when it is known that a generic drug will be available in the near future, a best estimate of the lower price of the ge...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200826070-00006

    authors: Hoyle M

    更新日期:2008-01-01 00:00:00

  • Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

    abstract::As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZITM) to submit evidence for the clinical and cost effectiveness of durvalumab for the treatment of patients with locally advanced, unresecta...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.1007/s40273-019-00870-w

    authors: Witlox WJA,van Asselt ADI,Wolff R,Armstrong N,Worthy G,Chalker A,Buksnys T,Stirk L,Kleijnen J,Joore MA,Grimm SE

    更新日期:2020-04-01 00:00:00

  • Economic evaluation of influenza vaccination and economic modelling. Can results be pooled?

    abstract::Scientific reviewing methods were applied to economic studies of influenza vaccination, and an economic model of influenza vaccination was developed from these primary sources. Issues arising from the secondary literature review include the quality of evidence on the effectiveness of the vaccines, the absence of a tra...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199600093-00015

    authors: Jefferson T,Demicheli V

    更新日期:1996-01-01 00:00:00

  • The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications.

    abstract:BACKGROUND:The apparent decrease in the rate of approval of new molecular entities has provoked extensive discussion and fears that the productivity of biopharmaceutical research and development has severely declined in recent years. OBJECTIVE:To investigate the extent to which traditional measures of innovative outpu...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200624002-00008

    authors: Berndt ER,Cockburn IM,Grépin KA

    更新日期:2006-12-01 00:00:00

  • Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy.

    abstract:OBJECTIVES:This study provides the results of a cost-effectiveness analysis of levetiracetam as an adjunctive treatment for refractory epilepsy from the Canadian Ministry of Health perspective. The main objective is to estimate the expected cost-effectiveness ratio expressed as the incremental cost per seizure-free day...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200523050-00008

    authors: Blais L,Sheehy O,St-Hilaire JM,Bernier G,Godfroid P,LeLorier JJ

    更新日期:2005-01-01 00:00:00

  • Clinical aspects of therapeutic substitution.

    abstract::A variety of problems are associated with the operation, quality, costs, and benefits of therapeutic substitution programmes. Adequate communication of procedures, events, and failures are essential features of a safe therapeutic substitution policy. However, case reports of suboptimal therapy and differences in pha...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199200011-00010

    authors: Levy RA

    更新日期:1992-01-01 00:00:00

  • A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting.

    abstract:BACKGROUND AND AIM:Buprenorphine offers an alternative to methadone in the treatment of heroin dependence, and has the advantage of allowing alternate-day dosing. This study is the first to examine the cost effectiveness of buprenorphine as maintenance treatment for heroin dependence in a primary care setting using eco...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-200523010-00007

    authors: Harris AH,Gospodarevskaya E,Ritter AJ

    更新日期:2005-01-01 00:00:00

  • Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data.

    abstract:BACKGROUND:Simulation models utilizing real-world data have potential to optimize treatment sequencing strategies for specific patient subpopulations, including when conducting clinical trials is not feasible. We aimed to develop a simulation model to estimate progression-free survival (PFS) and overall survival for fi...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00951-1

    authors: Degeling K,Wong HL,Koffijberg H,Jalali A,Shapiro J,Kosmider S,Wong R,Lee B,Burge M,Tie J,Yip D,Nott L,Khattak A,Lim S,Caird S,Gibbs P,IJzerman M

    更新日期:2020-11-01 00:00:00

  • Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

    abstract::The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost effectiveness of denosumab for the prevention of fragility fractures in post-menopausal women, as part of the Institute's single technology appraisal (STA...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11589310-000000000-00000

    authors: Scotland G,Waugh N,Royle P,McNamee P,Henderson R,Hollick R

    更新日期:2011-11-01 00:00:00

  • Epidemiology, therapy and costs of nosocomial infection.

    abstract::In the current climate of cost containment and quality control, nosocomial infection is a worrisome adverse event in hospital care. Hospitalised patients require care for increasingly severe illnesses, and are therefore more susceptible to infection, especially by opportunistic micro-organisms. It is thus necessary to...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/00019053-199507020-00005

    authors: Gálvez-Vargas R,Bueno-Cavanillas A,García-Martín M

    更新日期:1995-02-01 00:00:00

  • Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis.

    abstract::The annual cost of managing migraine totals billions of US dollars. This retrospective economic analysis of a clinical trial comparing subcutaneous dihydroergotamine mesylate (DHE) with subcutaneous sumatriptan in the treatment of acute migraine is appropriate because, although each product has been shown to be effica...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00019053-199610010-00006

    authors: Payne K,Kozma CM,Lawrence BJ

    更新日期:1996-07-01 00:00:00

  • The state of health economic research in South Africa: a systematic review.

    abstract:BACKGROUND:Economic factors are a limiting factor toward the implementation of many health programmes and interventions. Economic evaluation has a great potential to contribute toward cost-effective healthcare delivery in South Africa. Little is known about the characteristics and quality of health economic (including ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章,评审

    doi:10.2165/11589450-000000000-00000

    authors: Gavaza P,Rascati KL,Oladapo AO,Khoza S

    更新日期:2012-10-01 00:00:00

  • Future of Data Analytics in the Era of the General Data Protection Regulation in Europe.

    abstract::The development of evidence to demonstrate 'value for money' is regarded as an important step in facilitating the search for the optimal allocation of limited resources and has become an essential component in healthcare decision making. Real-world evidence collected from de-identified individuals throughout the conti...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.1007/s40273-020-00927-1

    authors: Kolasa K,Ken Redekop W,Berler A,Zah V,Asche CV

    更新日期:2020-10-01 00:00:00

  • Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France.

    abstract:OBJECTIVE:The objective of this study was to examine the cost effectiveness of fluvoxamine compared with tricyclic antidepressants (TCAs) in the treatment of patients with depressive episodes. DESIGN AND SETTING:A Markov process model was constructed to model the effectiveness, as measured by time without depression, ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-199814040-00009

    authors: Nuijten M,Hadjadjeba L,Evans C,van den Berg J

    更新日期:1998-10-01 00:00:00

  • Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

    abstract:OBJECTIVE:To estimate the cost effectiveness (from the UK NHS and personal social services perspective) of the cholinesterase inhibitors donepezil, rivastigmine and galantamine compared with usual care in the treatment of mild to moderately severe Alzheimer's disease. Patients had a mean age of 74 years, a mean disease...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200523120-00010

    authors: Green C,Picot J,Loveman E,Takeda A,Kirby J,Clegg A

    更新日期:2005-01-01 00:00:00

  • Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy.

    abstract::We estimated the cost effectiveness of adding the ACE inhibitor ramipril to conventional treatment in patients with heart failure after acute myocardial infarction. These estimates were based on the Acute Infarction Ramipril Efficacy (AIRE) study and on complementary Swedish healthcare resource use data for a subset o...

    journal_title:PharmacoEconomics

    pub_type: 临床试验,杂志文章

    doi:10.2165/00019053-199712020-00016

    authors: Erhardt L,Ball S,Andersson F,Bergentoft P,Martinez C

    更新日期:1997-08-01 00:00:00

  • Direct and indirect costs attributable to alcohol consumption in Germany.

    abstract:AIM:To estimate the direct and indirect costs of morbidity and mortality attributable to alcohol consumption in Germany from a societal perspective in 2002. METHODS:Using the concept of attributable risks and the prevalence-based approach, age- and gender-specific alcohol-attributable fractions for morbidity and morta...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200725070-00006

    authors: Konnopka A,König HH

    更新日期:2007-01-01 00:00:00

  • A parent-child dyad approach to the assessment of health status and health-related quality of life in children with asthma.

    abstract:BACKGROUND:Assessment of health state and health-related quality of life (HR-QOL) are limited by a child's age and cognitive ability. Parent-proxy reports are known to differ from children's reports. Simultaneous assessment using a parent-child dyad is an alternative approach. OBJECTIVE:Our objective was to assess the...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/11597890-000000000-00000

    authors: Ungar WJ,Boydell K,Dell S,Feldman BM,Marshall D,Willan A,Wright JG

    更新日期:2012-08-01 00:00:00

  • Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.

    abstract:BACKGROUND:Recent randomised trials have demonstrated a statistically significant effect of trastuzumab on disease-free survival when used as adjuvant therapy for human epidermal growth factor receptor 2 protein (HER2)-positive resectable early stage breast cancer, with a treatment course lasting either 9 or 52 weeks. ...

    journal_title:PharmacoEconomics

    pub_type: 杂志文章

    doi:10.2165/00019053-200725050-00006

    authors: Millar JA,Millward MJ

    更新日期:2007-01-01 00:00:00

  • Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand.

    abstract::Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand. ...

    journal_title:PharmacoEconomics

    pub_type: 已发布勘误

    doi:10.1007/s40273-018-0754-y

    authors: Chongmelaxme B,Phisalprapa P,Manthaisong R,Dilokthornsakul P,Chaiyakunapruk N

    更新日期:2019-02-01 00:00:00